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Abstract – The reaction of N-tert-butanesulfinyl imines 1 with 
1,3-dibromopropene (2), in the presence of indium metal, in saturated aqueous 
solution of sodium bromide, produced bromohomoallylamine derivatives 3 as a 
variable anti:syn mixture of diastereoisomers, with total facial diastereoselectivity, 
and moderate yields. These compounds were easily transformed into the 
corresponding vinyl aziridines 5 upon deprotonation with KHMDS in THF, taking 
place the intramolecular cyclization in a stereospecific manner in moderate to high 
yields  
INTRODUCTION 
Saturated three-membered heterocyclic compounds, such aziridines, have attracted increasing attention in 
recent years for different reasons. From a clinical point of view, different compounds, both natural and 
synthetic, that bear in their structure aziridine rings, display pharmacological activities. Some of these 
compounds are currently used to fight different types of cancer (bladder,1 lung,2 leukemia3), in the 
treatment of malaria4 and leishmaniasis,5 or as antimicrobials.6 In addition to the pharmacological interest, 
in recent years different aziridines have become important within the field of asymmetric synthesis, acting 
as metal ligands in a variety of stereoselective addition reactions of organozinc reagents to carbonyl 
compounds,7 in Henry-type reactions between nitro compounds and aldehydes,8 in aldol reactions,9 and 
hydroxylation reactions of olefins,10 among others. These compounds have also been used as chiral 
 
auxiliaries in different processes.11 The chemistry of aziridines, including synthetic procedures for their 
preparation, has been extensively reviewed.12 Of special interest are those methodologies which allow the 
formation of the aziridine ring in a stereoselective manner. There are three general strategies to reach the 
formation of the aziridine ring: (a) intramolecular nucleophilic substitution in amino compounds, (b) 
reaction between nitrenes or nitrenoids with olefins, and (c) reaction between carbenes or carbenoids with 
imines (Scheme 1). Following the general strategy (a), different stereoselective syntheses of aziridines 
from chiral N-tert-butanesulfinyl α-chloroimines have been reported. In these transformations, a 
diastereoselective nucleophilic addition to the imine takes place first, follow by the intramolecular 
cyclization. Hydride (reduction of the imine),13 Grignard reagents,14 organocerium compounds14c,15 and 
allylic tellurium salts16 were used as nucleophiles in these processes (Scheme 1). Aziridines were also 
prepared through a Corey-Chaykovsky reaction of chiral N-tert-butanesulfinyl aldimines and ketimines.17 
Importantly, vinyl aziridines were obtained when S-allyl tetrahydrothiophenium bromide18 was used as 




It is worth mentioning that N-tert-butanesulfinyl imines19 have found high applicability in synthesis as 
electrophiles, because they are accessible in large-scale processes in an enantiopure form,20 and practical 
processes for recycling the tert-butanesulfinyl group have also been reported.21 With regards to this, we 
have extensively studied the stereoselective allylation and propargylation of N-tert-butanesulfinyl 
imines22 and the application in synthesis of the resulting homoallyl amine derivatives.23 Continuing our 
interest in this topic, we herein report our approach to the indium-mediated addition of 
1,3-dibromopropene to N-tert-butanesulfinyl aldimines, with the aim of synthesize N-tert-butanesulfinyl 
 
aziridines, upon intramolecular cyclization of the expected β-bromohomoallylamine derivatives. To the 
best of our knowledge, there is only one report about the allylation of N-tert-butanesulfinyl aromatic 
aldimines with 1,3-dibromopropene, using zinc in THF at 50 ºC, to produce in moderate yields the 
corresponding trans-vinyl aziridines.24  
RESULTS AND DISCUSSION 
The starting N-tert-butanesulfinyl aldimines 1 were easily prepared by condensation of the corresponding 
aldehyde and (R)-tert-butanesulfinamide in the presence of 2 equiv of Ti(OEt)4 in THF at room 
temperature.25 No racemization occurred during the condensation process and the aldimines 1 exhibited 
exclusively E configuration. In order to find the best reaction conditions to carry out the allylation of 
aldimines 1 with 1,3-dibromopropene (2, commercially available as an almost equimolecular mixture of 
cis and trans isomers), we took the imine derived from isovaleraldehyde 1a as the model substrate. Thus, 
the reaction of imine 1a with 4 equivalents of 1,3-dibromopropene (2), in the presence of 4 equivalents of 
indium, at room temperature for 12 hours, in a saturated aqueous solution of sodium bromide led to a 
59/41 mixture of the expected bromohomoallylamine derivative 3a and the allylated product 4a, taking 
place a total consumption of starting imine 1a (Table 1, entry 1). Almost total disappearance of starting 
imine 1a with formation of similar ratios of compounds 3a/4a was observed working with less 
equivalents of both, indium (2 equivalents) and allylic bromide 2 (3 equivalents), under the same reaction 
conditions (Table 1, entry 2). On the other hand, when the reaction was performed in a larger excess of 
1,3-dibromopropene (2, 6 equivalents), the amount of the expected bromohomoallylamine derivative 3a 
in the reaction mixture was a little big higher (Table 1, entry 4). A similar result was also achieved when 
the allylindium intermediate was formed prior to the addition of the imine 1a (no Barbier reaction 
conditions) in the saturated aqueous solution of sodium bromide (Table 1, entry 3). Unfortunately, no 
reaction was observed working in THF and DMF at room temperature (Table 1, entries 5 and 7, 
respectively), and the conversion was very low when the reaction was carried out in THF at 60 ºC (Table 
1, entry 6). The allylation did not proceed at all using zinc instead of indium in a saturated aqueous 
solution of sodium bromide, at room temperature (Table 1, entry 8), and the conversions were very low in 
DMF and THF working at the same temperature (Table 1, entries 9 and 10). Finally, the treatment of 
dibromomo compound 2 with magnesium in THF for 2 hours at room temperature, followed by reaction 
of resulting solution with imine 1a at temperatures ranging from 0 to 23 ºC did not produced any of the 
allylated product, probably because of decomposition of the organomagnesium compound initially 
formed (Table 1, entry 11). At this point it is worth mentioning that in all cases the anti diastereomer of 
compound 3a was predominant (anti/syn around 70:30).    
 
 
Table 1. Optimization of the reaction of imine 1a and 1,3-dibromopropene (2)a 
Entry Metal (equiv) Solvent 2 (equiv) T (ºC) Conversion 3a/4a Ratiob 
1 In (4) sat. NaBr-H2O 4 23 >90 59/41 
2 In (2) sat. NaBr-H2O 3 23 >90 52/48 
3c In (1.5) sat. NaBr-H2O 3 23 >90 54/46 
4 In (1.8) sat. NaBr-H2O 6 23 >90 60/40 
5 In (1.5) THF 3 23 0 - 
6 In (1.5) THF 3 60 15 60/40 
7 In (1.5) DMF 3 23 0 - 
8 Zn (1.8) sat. NaBr-H2O 2 23 0 - 
9 Zn (1.8) DMF 2 23 10 50/50 
10 Zn (1.8) THF 2 23 20 54/46 
11c,d Mg (1.8) THF 2 -78 to 23 0 - 
a The reaction time was 12 hours, but in the case of entry 1, which was 4 hours. b Reaction products ratio was determined by 
1H-NMR analysis of the crude reaction mixtures. c The organometallic compound was prepared prior to the addition of the 
imine 1a, under no Barbier reaction conditions. d The reaction was set up at 0 ºC and the system was allowed to reach room 
temperature for 4 hours. 
 
We studied next the scope of the reaction of 1,3-dibromopropene (2) with different N-tert-butanesulfinyl 
aldimines 1, by applying the optimized conditions shown in Table 1, entry 2.  
We studied first the allylation of aliphatic aldimines 1a-d (Table 2). In the case of the imine derived from 
isovareladehyde 1a, product 3a was obtained in 37% yield (75:25 anti:syn ratio), and the dehalogenated 
product 4a in 26% yield, as a single diastereomeric. The aldimine derived from nonanal 1b led to the 
formation of the bromoallylation product 3b in 34% yield and a slightly worse diastereomeric ratio (68:32 
anti:syn ratio) than in 3a, while the byproduct 4b was isolated in 26% yield. On the other hand, compound 
4c was the only isolated product in 16% yield, in the reaction of the imine 1c, derived from 
cyclohexanecarbaldehyde. Finally, the imine 1d, derived from phenylacetaldehyd, reacted 
with1,3-dibromopropene (2) to give the bromoalylation product 3d in 33% isolated yield and a better 


































4a (26%, >95:5 dr)
4c (16%, >95:5 dr)
3a (37%, 75:25 dr) 3b (34%, 68:32 dr) 4b (26%, >95:5 dr)
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a Yields were determined for isolated compounds after column chromatography. b Diastereomeric ratios for compounds 3 refer 
to anti:syn ratios. 
 
Aromatic aldimines 1e-j displayed a different behavior from the aliphatic ones in these allylation reactions 
(Table 3). Thus, the reaction of the imine 1e, derived from benzaldehyde, at room temperature, led to the 
formation of the product 4e in 16% yield, the expected bromoallylated product being not isolated. On the 
other hand, the imine derived from para-methylbenzaldehyde 1f did not react under these reaction 
conditions, due probably to the weak electrophilic character of this aromatic imine with an 
electron-donating substituent. The imine derived from para-fluorobenzaldehyde 1g reacted with 
1,3-dibromopropene (2) to give the bromoallylated product 3g in 35% yield, and surprisingly, as a single 
anti diastereoisomer. In addition, the dehalogenated product 4g was also isolated in 34% yield. The imine 
of para-chlorobenzaldehyde 1h led to compound 3h also with a high diastereoselectivity but a considerably 
lower yield of 20%. In the case of the imine 1i with a trifluoromethyl substituent (strong 
electron-withdrawing group) at para position, the bromoallylation product 3i was isolated in 25% yield in 
an almost diastereoselective manner, and the dehalogenated product 4i was also obtained in 16% yield. 
 
Finally, the imine derived from furfural 1j did not give rise to the bromoallylated product, the product 4j 
being exclusively isolated in 10% yield.  
 

























4e (16%, >95:5 dr) 3g (35%, >95:5 dr) 4g (34%, >95:5 dr)
3h (20%, >95:5 dr) 4h (18%, >95:5 dr) 3i (25%, >95:5 dr) 4i (16%, >95:5 dr)










a Yields were determined for isolated compounds after column chromatography. b Diastereomeric ratios for compounds 3 refer 
to anti:syn ratios. 
 
A speculative mechanism, which explains the formation of products 3 and 4, is depicted on Scheme 2. 
Thus, metallation of 1,3-dibromopropene (2) produces allylindium A, which reacts with the chiral imine 1 
through a cyclic transition state, previously proposed in other alyllations of this type, in which the indium 
atom is coordinated with the nitrogen of the imine, and oxygen of the sulfinyl group. The addition of the 
 
allylindium system A, reacting at γ-position, takes place to the Si-face of the imine with RS configuration, 
giving rise to the desired bromoallylated product 3, as a mixture of anti:syn diastereoisomers. Being in the 
presence of an excess of metal (2 equivalents), after the first metallation, allylindium intermediate A could 
undergo a second metallation to generate the dianionic species B. Further reaction of B with imine 1 would 
produce allylindium intermediate C, precursor after hydrolysis of the allylated product 4. The formation of 
4 could also be explained from compound 3. Thus, in the presence of excess of indium, compound 3 could 
be reduced again by having a bromine in the allylic position and generating in this way intermediate C, 


















































The intramolecular cyclization of compounds 3 was carried out by deprotonation with a 1M solution of 
KHMDS in a 1:1 mixture of THF:toluene, at -78 °C to room temperature. Aliphatic substrates 3a,b,d were 
used as mixtures of anti:syn diastereomers to give trans and cis aziridines 5, which were easily isolated 
after chromatographic column purification. Aziridines 5a and 5d were obtained with moderate overall 
yields, close in both cases to 50% (Table 4, entries 1 and 3). The trans and cis aziridines 5 were isolated in 
practically the same ratio as the anti:syn ratio of their precursors 3 (the notation t and c as the second letter 
in the numbering of the aziridines refers to the trans and cis isomers, respectively). This shows that the 
cyclisation reaction is stereospecific, and takes place over intermediates in which the nucleophile and the 
leaving group meet in an anti-periplanar arrangement. In the case of the anti isomers, the elimination leads 
to the formation of the trans aziridines. Likewise, the syn diastereomers lead to the cis aziridines. In the case 
of aziridine derived from nonanal 5b, yields obtained were lower (Table 4, entry 2). On the contrary, 
aromatic aziridines 5gt, 5ht and 5it (Table 4, entries 3-6) were isolated with higher yields, being excellent 
for the one derived from para-trifluoromethylbenzaldehyde (Table 4, entry 6). 
 
The configuration of the aziridines 5 was determined by NOESY experiments. Bearing in mind that the 
cyclizations are diastereoselective, once the configuration of the aziridines 5 is known, it is possible to 
assign the configuration of the diastereomers from which they are derived. Thus, aziridines with relative 
trans configuration 5t come from bromoallylated compounds 3 with relative anti configuration, and vice 
versa. Since trans aziridines are the major products in these cyclizations, this implies that compounds 3 
with relative anti-configuration are the major component in the diastereomeric mixtures of the 
bromoallylation reactions. It is also conclusive to assign the relative configuration of the aziridines 5 the 
value of the coupling constants of the two heterocyclic protons in 1H NMR spectra. The values of these 
constants for cis protons are between 5.5 and 8.0 Hz, and in the case of trans, between 2.5 and 3.5 Hz. Both 
the NOESY experiments and the values of the coupling constants were concordant and allowed without any 
doubt the assignment of the configurations of the aziridines 5, and consequently, those of the 
bromoallylated compounds 3. 
In summary, a synthesis of N-tert-butanesulfinyl trans- and cis-vinyl aziridines 5 was carried out in two 
steps from both aliphatic, and aromatic N-tert-butanesulfinyl aldimines 1, and 1,3-dibromopropene (2). The 
bromoallylation of the imine is the key step of this synthetic strategy, the expecting products 3 being 
accessible in moderate yields from no sterically hindered aliphatic imines and aromatic imines bearing 
electron-withdrawing groups. The allyltions reactions take place with total facial diastereoselectivity, 
concerding the addition to the imine, leading also preferently to diastereisomers with anti relative 
configuration. The final intramolecular cyclization step proceed in a stereospecific manner to give 
aziridines 5 in moderate to high yields.    
EXPERIMENTAL 
All chemicals were commercially available (Acros, Aldrich). TLC was performed on Merck silica gel 60 
F254, using aluminum plates and visualized with phosphomolybdic acid (PMA) stain. Chromatographic 
purification was performed by flash chromatography using Merck silica gel 60 (0.040-0.063 mm) and 
different eluents. Low-resolution electron impact (EI) mass spectra were obtained at 70eV on Agilent 
GC/MS-5973N apparatus equipped with a HP-5MS column (Agilent technologies, 30 m × 0.25 mm) and 
high resolution mass spectra (HRMS-ESI) were obtained on a Waters LCT Premier XE apparatus 
equipped with a time of flight (TOF) analyzer and the samples were ionized by ESI techniques and 
introduced through an ultra-high pressure liquid chromatograph (UPLC) model Waters ACQUITY H 
CLASS.  IR spectra were measured (film) with a Nicolet Impact 510 P-FT Spectrometer. NMR spectra 
were recorded with a Bruker AC-300 and a Bruker 500-AVANCE IIIHD, using CDCl3 as solvent, and 
TMS as internal standard. Optical rotations were measured on a Perkin Elmer 341 polarimeter.  
 
 
Table 4. Synthesis of aziridines 5 from bromohomoalilamine derivatives 3a 
 
 Bromohomoallyl amine derivative 3 Aziridine 5 





















































a Yields were determined for isolated compounds after column chromatography. b A mixture of compounds 3 and 4 were used as 
starting materials in this transformation. 
 
 
Indium promoted reaction of imines 1 and 1,3-dibromopropene (2). General procedure. 
To a suspension of the corresponding imine 1 (0.5 mmol) in a saturated aqueous solution of sodium 
bromide (0.5 mL) was added 1,3-dibromopropne (2, 0.299 g, 0.149 mL, 1.5 mmol), and indium (0.115 g, 
1.0 mmol). The resulting mixture was stirred at 23 ºC for 12 h and after that, extracted with EtOAc (3 × 
15 mL). The organic layer was washed with brine (2 × 10 mL), dried over anhydrous MgSO4 and 
evaporated (15 Torr). The resulting residue was then purified by column chromatography (silica gel, 
hexane/EtOAc) to yield compounds 3 and 4. Yields are given on Tables 2 and 3. Physical and 
spectroscopic data follow. 
(RS,3S,4R)-3-Bromo-N-(tert-butanesulfinyl)-6-methylhept-1-en-4-amine (anti-3a).- Pale yellow oil; Rf  
0.55 (hexane/AcOEt 2:1); [α]30D -21 (c 0.50, CH2Cl2); IR (film) ν 3203, 2968, 1640, 1450, 1376, 1057 
cm–1; 1H RMN (300 MHz, CDCl3) δ 0.87 (3H, d, J = 6.5 Hz, CH3), 0.94 (3H, d, J = 6.7 Hz, CH3), 1.26 
[9H, s, (CH3)3], 1.58 (1H, ddd, J = 14.2, 10.0, 4.2 Hz, CH), 1.65–1.85 (1H, m, CH), 3.30 (1H, tt, J = 9.9, 
3.2 Hz, CH), 3.76 (1H, d, J = 9.7 Hz, NH), 5.11 (1H, dd, J = 8.9, 2.8 Hz, CH), 5.16–5.26 (1H, m, CH), 
5.39 (1H, dt, J = 16.8, 1.0 Hz, CH), 5.98 (1H, ddd, J = 16.8, 10.1, 8.9 Hz, CH); 13C RMN (100 MHz, 
CDCl3) δ 21.4 (CH3), 22.7 (CH3), 23.5 (CH3), 24.2 (CH), 40.1 (CH2), 56.4 (C), 59.2 (CH), 64.9 (CH), 119.2 
(CH2), 135.2 (CH); LRMS (EI) m/z 174 (M+-135, 36%), 133 (32), 125 (9), 113 (100), 83 (25), 57 (60); 
HRMS calcd for C12H24BrNOS (M+) 309.0762, founf 309.0755.  
(RS,3R*,4R)-3-Bromo-N-(tert-butanesulfinyl)-6-methylhept-1-en-4-amine (3a’).- Mixture of anti:syn 
diastereoisomers; yellow oil; Rf 0.55-0.48 (hexane/AcOEt 2:1); [α]30D -18 (c 0.75, CH2Cl2); IR (film) ν 
3203, 2968, 1640, 1450, 1376, 1057, 962 cm–1; 1H RMN (300 MHz, CDCl3) δ 0.85-0.95 (12H, m, CH3), 
1.23 [9H, s, (CH3)3], 1.26 [7.8H, s, (CH3)3], 1.50-1.75 (1H, m, CH), 1.65-1.85 (2.3H, m, CH), 3.30 (0.7H, 
m, CH), 3.49 (2H, m, CH, NH), 3.76 (1H, d, J = 9.7 Hz, NH), 4.82 (1H, d, J = 8.1 Hz, CH), 5.11 (0.7H, 
dd, J = 8.9, 2.8 Hz, CH), 5.20 (0.7H, d, J = 10.2 Hz, CH), 5.26 (1H, dd, J = 10.1, 1.2 Hz, CH), 5.40 (1.7H, 
m, CH), 6.00-6.50 (1.7H, m, CH); 13C RMN (100 MHz, CDCl3) δ 21.2 (CH3), 21.4 (CH3), 22.6 (CH3), 22.7 
(CH3), 23.4 (CH3), 23.5 (CH3), 24.2 (CH), 24.5 (CH3), 40.1 (CH2), 41.2 (CH2), 56.4 (C), 56.6 (C), 58.7 
(CH), 59.2 (CH), 59.8 (CH), 64.9 (CH), 119.2 (CH2), 120.4 (CH2), 134.6 (CH), 135.2 (CH).  
(RS,4R)-N-(tert-Butanesulfinyl)-6-methylhept-1-en-4-amine (4a)45.- Colourless liquid; 1H RMN (300 
MHz, CDCl3) δ 0.90 (6H, t, J = 6.6 Hz, CH3), 0.94 (3H, d, J = 6.7 Hz, CH3), 1.20 [9H, s, (CH3)3], 1.38 
(1H, m, CH), 1.74 (2H, dd, J = 9.6, 4.8 Hz, CH2), 3.18 (1H, d, J = 7.4 Hz, NH), 3.37 (1H, m, CH), 5.17 
(2H, m, CH), 5.79 (1H, ddd, J = 17.0, 12.1, 7.3 Hz, CH); 13C RMN (100 MHz, CDCl3) δ 22.0 (CH3), 22.7 
(CH3), 23.0 (CH3), 24.5 (CH), 41.1 (CH2), 44.6 (CH2), 53.7 (CH), 55.9 (C), 119.0 (CH2), 134.1 (CH). 
(RS,3S,4R)-3-Bromo-N-(tert-butanesulfinyl)dodec-1-en-4-amine (3b).- Colourless liquid; Rf 0.65 
(hexane/AcOEt 2:1); [α]30D –73 (c 0.56, CH2Cl2); IR (film) ν 2988, 2903, 1636, 1452, 1321, 1059, 857  
 
cm–1; 1H RMN (300 MHz, CDCl3) δ 0.88 (6H, t, J = 6.7 Hz, CH3), 1.26 [19H, s, (CH2)5, (CH3)3], 1.58 (2H, 
ddd, J = 14.2, 10.0, 4.2 Hz, CH), 3.25 (1H, m, CH), 3.77 (1H, d, J = 8.8 Hz, NH), 5.03 (1H, dd, J = 9.0, 
3.2 Hz, CH), 5.20 (1H, d, J = 10.2 Hz, CH), 5.38 (1H, d, J = 16.8 Hz, CH), 6.00 (1H, ddd, J = 16.8, 10.1, 
9.0 Hz, CH); 13C RMN (100 MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7 (CH3), 25.6 (CH2), 29.2 (CH2), 
29.3 (CH2), 29.4 (CH2), 31.1 (CH2), 31.8 (CH2), 56.4 (C), 60.8 (CH), 63.6 (CH), 119.2 (CH2), 135.3 (CH); 
LRMS (EI) m/z 311 (M+-57, 4%), 309 (4), 213 (10), 211 (9), 189 (100), 105 (16), 96 (45), 82 (12), 67 (34), 
57 (50); HRMS calcd for C16H32BrNOS (M+) 365.1388, founf 365.1379.   
(RS,3R*,4R)-3-Bromo-N-(tert-butanesulfinyl)-dodec-1-en-4-amine (3b’).- Mixture of anti:syn 
diastereoisomers; colourless oil; Rf 0.62 (hexane/AcOEt 2:1); [α]30D -63 (c 0.45, CH2Cl2); IR (film) ν 2989, 
2903, 1636, 1450, 1420, 1321, 1059, 987 cm–1; 1H RMN (300 MHz, CDCl3) δ 0.88 (3H, t, J = 6.7 Hz, CH3), 
1.23 [8.1H, s, (CH3)3], 1.26 [27H, s, (CH2)9, (CH3)3], 1.58 (2H, dd, J = 10.6, 6.0 Hz, CH2), 3.24 (1H, ddd, 
J = 8.6, 5.2, 2.4 Hz, CH), 3.28 (0.71H, dd, J = 8.9, 3.7 Hz, CH), 3.57 (0.68H, d, J = 9.1 Hz, NH), 3.76 
(1H, d, J = 8.8 Hz, NH), 4.79 (0.7H, dd, J = 9.9, 3.6 Hz, CH), 5.03 (1H, dd, J = 9.0, 3.2 Hz, CH), 5.20 
(1H, d, J = 10.2 Hz, CH), 5.25 (0.78H, dd, J = 10.1, 1.1 Hz, CH), 5.38 (1.7H, d, J = 16.8 Hz, CH), 
5.93-6.20 (1.8H, m, CH); 13C RMN (100 MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7 (CH3), 22.9 (CH3), 
25.6 (CH2), 29.2 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 30.8 (CH2), 31.1 (CH2), 31.8 
(CH2), 32.0 (CH2), 55.2 (C), 56.4 (C), 59.2 (CH), 60.8 (CH), 61.3 (CH) 63.6 (CH), 119.2 (CH2), 120.5 
(CH2), 133.9 (CH), 135.3 (CH). 
(RS,4R)-N-(tert-Butanesulfinyl)dodec-1-en-4-amine (4b)45.- Colourless liquid; 1H RMN (300 MHz, 
CDCl3) δ 0.88 (3H, t, J = 6.7 Hz, CH3), 1.20 [9H, s, (CH3)3], 1.26 (12H, s, CH2), 1.53 (2H, m, CH2), 2.35 
(2H, m, , CH), 3.22 (1H, d, J = 6.2 Hz, NH), 3.30 (1H, m, CH), 5.15 (2H, dd, J = 13.7, 1.3 Hz, CH), 
5.74-5.80 (1H, m, CH); 13C RMN (100 MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7 (CH3), 25.7 (CH2), 
29.2 (CH2), 29.4 (CH2), 29.5 (CH2), 31.1 (CH2), 31.8 (CH2), 39.8 (CH2), 56.3 (C), 60.1 (CH), 119.0 (CH2), 
135.1 (CH).  
(RS,2R,3S)-3-Bromo-N-(tert-butanosulfinyl)-1-phenylpent-4-en-2-amine (3d).- Colourless oil; Rf 0.38 
(hexane/AcOEt 2:1); [α]30D -100 (c 1.05, CH2Cl2); IR (film) ν 3020, 2925, 1642, 1452, 1312, 1201, 1049, 
896 cm–1; 1H RMN (300 MHz, CDCl3) δ 1.08 [9H, s, (CH3)3], 2.91 (1H, m, CH2), 3.63 (1H, m, CH), 3.80 
(1H, d, J = 8.3 Hz, NH), 4.98 (1H, dd, J = 9.0, 3.2 Hz, CH), 5.28 (1H, d, J = 10.2 Hz, CH), 5.42 (1H, d, J 
= 16.8 Hz, CH), 6.09 (1H, m, CH), 7.00-7.30 (5H, m, CH); 13C RMN (100 MHz, CDCl3) δ 22.4 (CH3), 
37.7 (CH2), 56.3 (C), 62.2 (CH), 62.3 (CH), 119.8 (CH2), 126.6 (CH), 128.4 (CH), 129.5 (CH), 134.0 
(CH), 137.5 (C); LRMS (EI) m/z 289 (M+-56, 7%), 287 (8), 240 (14), 238 (11), 198 (32), 196 (44), 182 
(52), 180 (48), 145 (30), 117 (32), 91 (100); HRMS calcd for C15H22BrNOS (M+) 343.0605, found 
343.0599. 
 
(RS,2R,3R*)-3-Bromo-N-(tert-butanesulfinyl)-1-phenylpent-4-en-2-amine (3d’).- Mixture of anti:syn 
diastereoisomers; colourless oil; Rf 0.34 (hexane/AcOEt 2:1); [α]30D -93 (c 0.68, CH2Cl2); IR (film) ν 3020, 
2925, 1642, 1452, 1312, 1121, 1049 cm–1; 1H RMN (300 MHz, CDCl3) δ 1.08 [15H, s, (CH3)3], 2.88-2.94 
(1H, m, CH2), 3.61-3.64 (1H, m, CH), 3.75-3.80 (1H, d, J = 8.4 Hz, NH), 4.74 (0.69 H, d, J = 9.6 Hz, 
CH), 4.98 (1H, dd, J = 9.0, 3.2 Hz, CH), 5.25-5.45 (3.6H, m, CH), 6.00-6.30 (1.7H, m, CH), 7.15-7.30 
(11H, m, CH); 13C RMN (100 MHz, CDCl3) δ 22.4 (CH3), 37.7 (CH2), 39.6 (CH2), 56.3 (C), 56.5 (C), 62.2 
(CH), 62.3 (CH), 62.7 (CH), 119.8 (CH2), 120.3 (CH2), 126.6 (CH), 126.7 (CH), 128.4 (CH), 128.6 (CH), 
129.3 (CH), 129.5 (CH), 134.8 (CH), 134.9 (CH), 137.5 (C), 137.6 (C); LRMS (EI) m/z 211 (M+-132, 
10%), 150 (100), 148 (97), 91 (70);  
(RS,2R)-N-(tert-Butanesulfinyl)-1-phenylpent-4-en-2-amine (4d)45.- Colourless liquid; 1H RMN (300 
MHz, CDCl3) δ 1.07 [9H, s, (CH3)3], 2.37-2.41 (2H, m, CH2), 2.83 (2H, m, CH2), 3.33 (1H, d, J = 5.7 Hz, 
NH), 3.55-3.59 (1H, m, CH), 5.17 (2H, m, CH), 5.80-5.84 (1H, m, CH), 7.15-7.30 (5H, m, CH); 13C 
RMN (100 MHz, CDCl3) δ 22.4 (CH3), 37.7 (CH2), 56.3 (C), 62.2 (CH), 62.3 (CH), 119.8 (CH2), 126.6 
(CH), 128.4 (CH), 129.5 (CH), 134.0 (CH), 137.5 (C). 
(RS,1R)-N-(terc-Butanosulfinil)-1-fenilbut-3-en-1-amina (4e)45.- Colourless liquid; 1H RMN (300 MHz, 
CDCl3) δ 1.20 [9H, s, (CH3)3], 2.35-2.60 (2H, m, CH2), 3.69 1(H, br s, NH), 4.47 (1H, ddd, J = 7.9, 5.4, 
2.2 Hz, CH), 5.20 (2H, dd, J = 7.7, 0.9 Hz, CH), 5.70-5.76 (1H, m, CH), 7.30-7.35 (5H, m, CH); 13C 
RMN (100 MHz, CDCl3) 22.5 (CH3), 43.3 (CH2), 55.5 (CH), 57.1 (C), 119.1 (CH2), 127.4 (CH), 127.6 
(CH), 128.3 (CH), 134.1 (CH), 141.6 (C). 
(RS,1R,2S)-2-Bromo-N-(tert-butanesulfinyl)-1-(4-fluorophenyl)but-3-en-1-amine (3g).- Pale yellow 
oil; Rf 0.25 (hexane/AcOEt 2:1); [α]30D -49 (c 1.20, CH2Cl2); IR (film) ν 3050, 2963, 1650, 1599, 1490, 
1369, 1080, cm–1; 1H RMN (300 MHz, CDCl3) δ 1.22 [9H, s, (CH3)3], 4.04 (1H, d, J = 2.2 Hz, NH), 4.59 
(1H, dd, J = 6.1, 2.5 Hz, CH), 4.65 (1H, dd, J = 9.6, 6.1 Hz, CH), 5.22 (1H, dd, J = 10.1, 0.6 Hz, CH), 
5.29 (1H, d, J = 16.9 Hz, CH), 5.93 (1H, dt, J = 16.9, 9.9 Hz, CH), 7.21 (2H, d, J = 8.4 Hz, CH), 7.49 (2H, 
d, J = 8.5 Hz, CH); 13C RMN (100 MHz, CDCl3) δ 22.6 (CH3), 56.1 (C), 58.6 (CH), 61.8 (CH), 120.2 
(CH2), 122.7 (C), 130.6 (CH), 131.5 (CH), 134.8 (CH), 136.3 (C); LRMS (EI) m/z 289 (M+-57, 8%), 255 
(60), 253 (50), 211 (62), 209 (62), 183 (20), 130 (100), 115 (28); HRMS calcd for C14H19BrFNrOS (M+) 
347.0355, found 347.0356.  
(RS,1R)-N-(tert-Butanesulfinyl)-1-(4-fluorophenyl)but-3-en-1-amine (4g)45.- Colourless liquid; 1H 
RMN (300 MHz, CDCl3) δ 1.19 [9H, s, (CH3)3], 2.40-2.60 (2H, m, CH2), 3.68 (1H, s, NH), 4.41-4.46 (1H, 
m, CH), 5.15-5.19 (2H, m, CH2), 5.68-5.71 (1H, m, CH), 7.20 (2H, d, J = 8.4 Hz, CH), 7.47 (2H, d, J = 
8.4 Hz, CH); 13C RMN (100 MHz, CDCl3) δ 22.6 (CH3), 43.2 (CH2), 55.2 (C), 58.6 (CH), 120.2 (CH2), 
129.2 (CH), 129.4 (CH), 131.6 (CH), 132.1 (C), 140.7 (C).  
 
(RS,1R,2S)-2-Bromo-N-(tert-butanesulfinyl)-1-(4-chlorophenyl)but-3-en-1-amine (3h).- Colourless 
oil; Rf 0.20 (hexane/AcOEt 2:1); [α]30D –43 (c 0.52, CH2Cl2); IR (film) ν 3056, 2963, 1648, 1595, 1475, 
1362, 1225, 1107 cm–1; 1H RMN (300 MHz, CDCl3) δ 1.22 [9H, s, (CH3)3], 4.06 (1H, d, J = 1.9 Hz, NH), 
4.58-4.68 (2H, m, CHN, CHBr), 5.23 (1H, d, J = 10.7 Hz, CH), 5.29 (1H, d, J = 16.9 Hz, CH), 7.26 (2H, 
m, CH), 7.34 (2H, m, CH); 13C RMN (100 MHz, CDCl3) δ 22.6 (CH3), 55.6 (CH), 56.0 (C), 59.5 (CH), 
120.1 (CH2), 129.0 (CH), 129.4 (CH), 129.5 (CH), 131.9 (C), 135.3 (C); LRMS (EI) m/z 246 (M+-119, 3%), 
244 (5), 211 (30), 209 (11), 189 (7), 187 (19), 167 (36), 165 (100), 141 (22), 139 (7), 115 (15); HRMS calcd 
for C10H11BrClNOS (M+-C4H8) 306.9433, found 306.9422.  
(RS,1R)-N-(tert-Butanesulfinyl)-1-(4-chlorophenyl)but-3-en-1-amine (4h)45.- Colourless oil; 1H RMN 
(300 MHz, CDCl3) δ 1.19 [9H, s, (CH3)3], 2.30-2.60 (2H, m, CH2), 3.68 (1H, s, NH), 4.44 (1H, t, J = 6.9 
Hz, CH), 5.16 (2H, dd, J =11.0, 6.3 Hz, CH2), 5.65-5.69 (1H, m, CH), 7.20-7.35 (4H, m, CH); 13C RMN 
(100 MHz, CDCl3) δ 22.6 (CH3), 43.3 (CH2), 55.2 (CH), 55.7 (C), 120.4 (CH2), 128.7 (CH), 129.1 (CH), 
129.2 (CH), 131.1 (C), 134.3 (C). 
(RS,1R,2S)-2-Bromo-N-(tert-butanesulfinyl)-1-(4-trifluoromethylphenyl)but-3-en-1-amine (3i).- 
Yellow oil; Rf 0.23 (hexane/AcOEt 2:1); [α]30D -50 (c 0.75, CH2Cl2); IR (film) ν 3046, 2958, 1650, 1452, 
1327, 1245, 926 cm–1; 1H RMN (300 MHz, CDCl3) δ 1.23 [9H, s, (CH3)3], 4.09 (1H, br s, NH), 4.60-4.80 
(2H, m, CHN, CHBr), 5.24 (1H, d, J = 10.2 Hz, CH), 5.31 (1H, d, J = 16.9 Hz, CH), 7.46 (2H, d, J = 8.1 
Hz, CH), 7.62 (2H, d, J = 8.2 Hz, CH); 13C RMN (100 MHz, CDCl3) δ 22.5 (CH3), 56.2 (C), 58.4 (CH), 
61.9 (CH), 120.4 (CH2), 125.2 (C), 129.3 (CH), 134.6 (CH), 141.4 (C); LRMS (EI) m/z 207 (M+-190, 6%), 
144 (57), 129 (100), 115 (35), 91 (43), 77 (17); HRMS calcd for C11H10BrF3N (M+-C4H10OS) 291.9949, 
found 291.9954. 
(RS,1R)-N-(tert-Butanesulfinyl)-1-(4-trifluorophenyl)but-3-en-1-amine (4i)45.- Colourless oil; 1H 
RMN (300 MHz, CDCl3) δ 1.21 [9H, s, (CH3)3], 2.40-2.60 (2H, m, CH2), 3.75 (1H, br s, NH), 4.52-4.58 
(1H, m, CH), 5.27-5.32 (2H, m, CH2), 5.67-5.72 (1H, m, CH), 7.46 (2H, d, J = 8.1 Hz, CH), 7.62 (2H, d, 
J = 8.1 Hz, CH); 13C RMN (100 MHz, CDCl3) δ 22.5 (CH3), 56.2 (C), 58.4 (CH), 61.9 (CH), 120.4 (CH2), 
125.2 (C), 129.3 (CH), 134.6 (CH), 141.4 (C). 
(RS,1R)-N-(tert-Butanesulfinyl)-1-(2-furyl)but-3-en-1-amine (4j)45.- Colourless oil; 1H RMN (300 
MHz, CDCl3) δ 1.21 [9H, s, (CH3)3], 2.40-2.60 (2H, m, CH2), 3.75 (1H, br s, NH), 4.52-4.58 (1H, m, CH), 
5.27-5.32 (2H, m, CH2), 5.67-5.72 (1H, m, CH), 7.46 (2H, d, J = 8.1 Hz, CH), 7.62 (2H, d, J = 8.1 Hz, 
CH); 13C RMN (100 MHz, CDCl3) δ 22.5 (CH3), 56.2 (C), 58.4 (CH), 61.9 (CH), 120.4 (CH2), 125.2 (C), 
129.3 (CH), 134.6 (CH), 141.4 (C). 
 
Synthesis of aziridines 5 from bromohomoallylamine derivatives 3. General procedure. 
 
To a solution of bromohomoallylamine derivative 3 (0.1 mmol) in THF (1.0 mL) was added dropwise at 
-78 ºC a 1M solution of KHMDS in a 1:1 mixture of THF:tolune (0.200 mL, 0.2 mmol). The reaction 
mixture was allowed to reach room temperature, and after that, it was stirred at the same temperature for 
3 h. Solvents were evaporated (15 Torr), and the resulting residue was hydrolyzed with brine (10 mL), 
extracted with EtOAc (3 × 15 mL). The organic layer was dried over anhydrous MgSO4 and evaporated 
(15 Torr). The resulting residue was then purified by column chromatography (silica gel, hexane/EtOAc) 
to yield pure compounds 5. Yields are given on Table 4. Physical and spectroscopic data follow. 
(RS,2R,3S)-N-(tert-Butanesulfinyl)-2-isobutyl-3-vinylaziridine (5ac).- Colourless oil; Rf 0.90 
(hexane/AcOEt 2:1); [α]30D -97 (c 0.86, CH2Cl2); IR (film) ν 2960, 2930, 1636, 1457, 1382, 1080 cm–1; 1H 
RMN (300 MHz, CDCl3) δ 0.90-0.97 (6H, m, CH3), 1.20 [9H, s, (CH3)3], 1.50-1.60 (2H, m, CH2), 
1.70-1.80 (1H, m, CH), 2.35 (1H, dd, J = 13.2, 6.9 Hz, CH), 3.17-3.22 (1H, m, CH), 5.31 (1H, dd, J = 
10.3, 1.6 Hz, CH), 5.40 (1H, dd, J = 17.2, 1.2 CH), 5.69 (1H, ddd, J = 17.2, 10.3, 8.1 Hz, CH); 13C RMN 
(100 MHz, CDCl3) δ 22.5 (CH3), 22.6 (CH2), 22.8 (CH3), 35.8 (CH), 36.2 (CH2), 38.3 (CH), 56.7 (C), 120.2 
(CH2), 132.4 (CH); LRMS (EI) m/z 173 (M+-56, 17%), 124 (29), 110 (83), 95 (60), 57 (100); HRMS calcd 
for C8H15NOS (M+-C4H8) 173.0874, found 173.0886. 
(RS,2R,3R)-N-(tert-Butanesulfinyl)-2-isobutyl-3-vinylaziridine (5at).- Colourless oil; Rf 0.82 
(hexane/AcOEt 2:1); [α]30D -80 (c 1.15, CH2Cl2); IR (film) ν 2960, 2930, 1636, 1475, 1386, 1262, 1092, 
902 cm–1; 1H RMN (300 MHz, CDCl3) δ 0.92-0.97 (6H, m, CH3), 1.26 [9H, s, (CH3)3], 1.38-1.42 (1H, m, 
CH), 1.79-1.83 (2H, m, CH2), 2.52-2.57 (1H, m, CH), 2.77 (1H, dd, J =9.0, 3.9 Hz, CH), 5.20-5.26 (1H, 
m, CH), 5.34-5.39 (1H, m, CH), 5.98 (1H, ddd, J = 17.2, 10.2, 9.0 Hz, CH); 13C RMN (100 MHz, CDCl3) 
δ 22.3 (CH3), 22.9 (CH3), 27.1 (CH3), 39.4 (CH2), 43.2 (CH), 50.2 (CH), 56.9 (C), 119.0 (CH2), 135.0 
(CH); LRMS (EI) m/z 229 (M+, 2%), 173 (8), 124 (16), 110 (66), 67 (36), 57 (100); HRMS calcd for 
C8H15NOS (M+-C4H8) 173.0874, found 173.0875. 
(RS,2R,3S)-N-(tert-Butanesulfinyl)-2-octyl-3-vinylaziridine (5bc).- Colourless oil; Rf 0.90 
(hexane/AcOEt 2:1); [α]30D -90 (c 0.50, CH2Cl2); IR (film) ν 2985, 2970, 2902, 1633, 1460, 1370, 1215, 
1078, 901 cm–1; 1H RMN (300 MHz, CDCl3) δ 0.88 (3H, t, J = 6.8 Hz, CH3), 1.21 [9H, s, (CH3)3], 
1.18-1.30 [12H, m, (CH2)6], 1.47-1.52 (2H, m, CH2), 2.31 (1H, dd, J = 13.4, 6.5 Hz, CH), 3.20 (1H, dd, J 
= 7.9, 7.2 Hz, CH), 5.32 (1H, dd, J = 10.3, 1.3 Hz, CH), 5.40 (1H, ddd, J = 17.2, 1.7, 0.6 Hz, CH), 
5.61-5.80 (1H, m, CH); 13C RMN (100 MHz, CDCl3) δ 14.1 (CH3), 22.7 (CH2), 22.9 (CH3), 27.0 (CH2), 
27.3 (CH2), 29.2 (CH2), 29.4 (CH2), 29.7 (CH2), 31.9 (CH2), 36.1 (CH), 39.5 (CH), 56.8 (C), 120.3 (CH2), 
132.2 (CH); LRMS (EI) m/z 172 (M+-113, 2%), 113 (60), 109 (19), 96 (33), 82 (12), 67 (34), 57 (100); 
HRMS calcd for C16H31NOS (M+) 285.2126, found 285.2138. 
(RS,2R,3R)-N-(tert-Butanesulfinyl)-2-octyl-3-vinylaziridine (5bt).- Colourless oil; Rf 0.83 
 
(hexane/AcOEt 2:1); [α]30D -88 (c 0.40, CH2Cl2); IR (film) ν 2985, 2970, 1633, 1460, 1370, 1218, 1078, 
920 cm–1; 1H RMN (300 MHz, CDCl3) δ 0.88 (3H, t, J = 6.8 Hz, CH3), 1.22-1.30 [21H, m, (CH2)6,  
(CH3)3], 2.51-2.55 (1H, m, CH), 2.78 (1H, dd, J = 9.0, 3.9, CH), 5.22 (1H, dd, J = 10.2, 1.2 Hz, CH), 5.37 
(1H, dd, J = 17.1, 1.0 Hz, CH), 5.90-6.04 (H, m, CH); 13C RMN (100 MHz, CDCl3) δ 14.1 (CH3), 22.6 
(CH2), 22.9 (CH3), 27.0 (CH2), 27.3 (CH2), 29.2 (CH2), 29.3 (CH2), 29.7 (CH2), 31.8 (CH2), 44.4 (CH), 
49.6 (CH), 56.9 (C), 118.9 (CH2), 135.1 (CH); LRMS (EI) m/z 180 (M+-105, 4%), 172 (1), 160 (5), 126 
(40), 113 (100), 105 (6); HRMS calcd for C12H23NOS (M+-C4H8) 229.1500, found 229.1508. 
(RS,2R,3S)-2-Benzyl-N-(tert-butanesulfinyl)-3-vinylaziridine (5dc).- Pale yellow oil; Rf 0.79 
(hexane/AcOEt 2:1); [α]30D -34 (c 0.63, CH2Cl2); IR (film) ν 3015, 2925, 1640, 1425, 1310, 949 cm–1; 1H 
RMN (300 MHz, CDCl3) δ 1.22 [9H, s, (CH3)3], 2.58 (1H, dd, J = 13.2, 7.0 Hz, CH), 2.82-2.86 (1H, m, 
CH2), 3.30 (1H, dd, J = 7.3, 7.1 Hz, CH), 5.35-5.56 (2H, m, CH), 5.84 (1H, ddd, J = 17.3, 10.3, 7.7 Hz, 
CH), 7.20-7.35 (5H, m, CH); 13C RMN (100 MHz, CDCl3) δ 22.8 (CH3), 33.7 (CH2), 36.1 (CH), 40.0 
(CH), 56.8 (C), 120.8 (CH2), 126.5(CH), 128.5 (CH), 128.7 (CH), 131.8 (CH), 138.3 (C); LRMS (EI) m/z  
207 (M+-56, 8%), 144 (58), 129 (100), 115 (34), 91 (38); HRMS calcd for C15H21NOS (M+) 263.1344, 
found 263.1354.  
(RS,2R,3R)-2-Benzyl-N-(tert-butanesulfinyl)-3-vinylaziridine (5dt).- Yellow oil; Rf 0.72 
(hexane/AcOEt 2:1); [α]30D -28 (c 0.60 CH2Cl2); IR (film) ν 3015, 2925, 1640, 1425, 1310, 1245, 1102 
cm–1; 1H RMN (300 MHz, CDCl3) δ 1.27 [9H, s, (CH3)3], 2.76-2.85 (1H, m, CH),  2.86-3.02 (1H, m, 
CH2), 3.11 (1H, dd, J = 14.5, 5.1 Hz, CH), 5.22 (1H, dd, J = 10.2, 1.3 Hz, CH), 5.38 (1H, dd, J = 17.3, 
1.1 Hz, CH), 6.00 (1H, J =17.1, 10.2, 9.0 Hz, CH), 7.06-7.46 (5H, m, CH); 13C RMN (100 MHz, CDCl3) δ 
22.9 (CH3), 37.1 (CH2), 44.1 (CH), 50.0 (CH), 57.1 (C), 119.4 (CH2), 126.7 (CH), 128.5 (CH), 128.8 (CH), 
134.6 (CH), 137.7 (C); LRMS (EI) m/z 207 (M+-56, 6%), 144 (57), 129 (100), 115 (35), 91 (43), 77 (17); 
HRMS calcd for C15H21NOS (M+) 263.1344, found 263.1350. 
(RS,2R,3R)-N-(terct-Butanesulfinyl)-2-(4-fluorophenyl)-3-vinylaziridine (5gt).- White solid; mp 64-66 
ºC (hexane/CH2Cl2); Rf 0.65 (hexane/AcOEt 2:1); [α]30D -20 (c 0.83 CH2Cl2); IR (film) ν 3050, 2963, 1648, 
1490, 1369, 1080, 967 cm–1; 1H RMN (300 MHz, CDCl3) δ 1.28 [9H, s, (CH3)3], 3.12 (1H, dd, J = 9.4, 3.5 
Hz, CH), 3.51 (1H, d, J = 3.5 Hz, CH), 5.36 (1H, dd, J = 10.2, 0.8 Hz, CH), 5.47 (1H, dd, J = 17.0, 0.7 
Hz, CH), 6.22-6.27 (1H, m, CH), 7.16 (2H, d, J = 8.4 Hz, CH), 7.47 (2H, d, J = 8.5 Hz, CH); 13C RMN 
(100 MHz, CDCl3) δ 23.0 (CH3), 43.8 (CH), 54.2 (CH), 57.5 (C), 121.0 (CH2), 121.9 (C), 128.0 (CH), 
131.8 (CH), 133.0 (CH2), 135.8 (C); LRMS (EI) m/z 210 (M+-57, 22%), 208 (22), 129 (100); HRMS calcd 
for C10H9FN (M+-C4H9OS) 162.0719, found 162.0724. 
(RS,2R,3R)-N-(tert-Butanesulfinyl)-2-(4-chlorophenyl)-3-vinylaziridine (5ht).- White solid; mp 67-69 
ºC (hexane/CH2Cl2); Rf 0.60 (hexane/AcOEt 2:1); [α]30D -19 (c 0.86, CH2Cl2); IR (film) ν 2963, 1645, 
 
1595, 1475, 1220, 897 cm–1; 1H RMN (300 MHz, CDCl3) δ 1.28 [9H, s, (CH3)3], 3.12 (1H, dd, J = 9.4, 3.5 
Hz, CH), 3.52 (1H, d, J = 3.5 Hz, CH), 5.36 (1H, dd, J = 10.2, 1 Hz, CH), 5.47 (1H, dd, J = 16.3, 1 Hz, 
CH), 6.25 (1H, ddd, J = 17.0, 10.1, 9.5 Hz, CH), 7.21 (2H, d, J = 8.4 Hz, CH), 7.32 (2H, d, J = 8.5 Hz, 
CH); 13C RMN (100 MHz, CDCl3) δ 23.0 (CH3), 43.8 (CH), 54.2 (CH), 57.5 (C), 121.0 (CH2), 127.6 (CH), 
128.8 (CH), 133.0 (CH), 133.8 (C), 135.8 (C); LRMS (EI) m/z 207 (M+-56, 6%), 144 (57), 129 (100), 115 
(35), 91 (43), 77 (17); HRMS calcd for C14H18ClNOS (M+) 283.0798, found 283.0789. 
(RS,2R,3R)-N-(tert-Butanesulfinyl)-2-(4-trifluoromethylphenyl)-3-vinylaziridine (5it).- Orange solid; 
mp 74-66 ºC (hexane/CH2Cl2); Rf 0.61 (hexane/AcOEt 2:1); [α]30D -28 (c 0.75, CH2Cl2); IR (film) ν 2958, 
1648, 1452, 1327, 1300, 1245 cm–1; 1H RMN (300 MHz, CDCl3) δ 1.29 [9H, s, (CH3)3], 3.16 (1H, dd, J = 
9.5, 3.5 Hz, CH), 3.61 (1H, d, J = 3.5 Hz, CH), 5.38 (1H, d, J = 10.6 Hz, CH), 5.48 (1H, d, J = 16.5 Hz, 
CH), 6.20-6.40 (1H, m, CH), 7.40 (2H, d, J = 8.1 Hz, CH), 7.61 (2H, d, J = 8.2 Hz, CH); 13C RMN (100 
MHz, CDCl3) δ 23.0 (CH3), 43.6 (CH), 54.6 (CH), 57.6 (C), 121.2 (CH2), 125.6 (CH), 125.7 (CH), 126.6 
(CH), 132.9 (CH), 140.1 (C); LRMS (EI) m/z 207 (M+ – 56, 6%), 144 (57), 129 (100), 115 (35), 91 (43), 77 
(17); HRMS calcd for C15H18F3NOS (M+) 317.1061, found 317.1064. 
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